Current Development on HIV-1 Protease Inhibitors

Author(s): Ornjira Aruksakunwong , Siriporn Promsri , Kitiyaporn Wittayanarakul , Piyarat Nimmanpipug , Vannajan S. Lee , Atchara Wijitkosoom , Pornthep Sompornpisut , Supot Hannongbua .

Journal Name: Current Computer-Aided Drug Design

Volume 3 , Issue 3 , 2007

Become EABM
Become Reviewer


Although a number of potent and selective inhibitors have been developed and approved as drugs for the treatment of HIV infection, efforts still needed in order to develop new inhibitors that are more potent, have unique resistance patterns, and minimal side effects. This review focuses to the HIV-1 protease (HIV-1 PR), the enzyme belongs to the family of aspartic acid based on the identification of the Asp-Thr-Gly catalytic triad. In the first part, general features of the HIV-1 PR as well as its structure and functions were given. Afterwards, the review was targeted to discovery, characteristic, activity and emergence of drug resistant of the nine FDA (Food and Drug Administration) approval inhibitors, indinavir, saquinavir, nelfinavir, ritonavir, lopinavir, amprenavir, tipranavir, atazanavir and fosamprenavir. In addition, the two promising inhibitors (brecanavir, darunavir), which are currently under development, as well as a competitive non-peptide based inhibitors (water soluble C60 derivatives) were also introduced.

Keywords: HIV-1 protease, protease inhibitor, nonpeptidic inhibitor, drug resistance and C60 derivatives

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [201 - 213]
Pages: 13
DOI: 10.2174/157340907781695431
Price: $58

Article Metrics

PDF: 4